Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 09, 2018 16:15 ET | Source: ARCA biopharma, Inc.

ARCA biopharma Announces Second Quarter 2018 Financial Results and Provides Corporate Update

WESTMINSTER, Colo., Aug. 09, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
July 31, 2018 08:30 ET | Source: ARCA biopharma, Inc.

ARCA Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting With FDA on Gencaro Development for Atrial Fibrillation

Single Phase 3 trial may be sufficient for approval of atrial fibrillation indicationPhase 3 clinical trial Special Protocol Assessment submission anticipated 3Q2018Gencaro is in development as...
May 29, 2018 08:30 ET | Source: ARCA biopharma, Inc.

GENETIC-AF Phase 2B Clinical Trial Results Presented in Late Breaking Presentation at European Society of Cardiology Heart Failure 2018 World Congress

WESTMINSTER, Colo., May 29, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
May 10, 2018 08:30 ET | Source: ARCA biopharma, Inc.

ARCA biopharma Announces Phase 2B GENETIC-AF Clinical Trial Results Selected for Late Breaking Oral Presentation at European Society of Cardiology Heart Failure 2018 World Congress

WESTMINSTER, Colo., May 10, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
May 08, 2018 16:15 ET | Source: ARCA biopharma, Inc.

ARCA Biopharma announces first quarter 2018 financial results AND Provides Corporate Update

WESTMINSTER, Colo., May 08, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
April 23, 2018 08:30 ET | Source: ARCA biopharma, Inc.

ARCA biopharma and Medtronic Extend Gencaro Clinical Trial Collaboration Agreement

WESTMINSTER, Colo., April 23, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
March 22, 2018 16:30 ET | Source: ARCA biopharma, Inc.

ARCA biopharma Announces Fiscal Year 2017 Financial Results and Provides Corporate Update

WESTMINSTER, Colo., March 22, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
February 26, 2018 08:00 ET | Source: ARCA biopharma, Inc.

ARCA biopharma Reports Topline Phase 2B Results for GENETIC-AF Clinical Trial

-------------------------------------------------------------------------------------------------- Gencaro Demonstrates Comparable Efficacy to Active Control and Trend for Potential Gencaro...
January 08, 2018 08:30 ET | Source: ARCA biopharma, Inc.

ARCA biopharma Announces Completion of GENETIC-AF Phase 2B Clinical Trial

-------------------------------------------------------------------------------------------------- GENETIC-AF Evaluating Gencaro as Potentially First Genetically-Targeted Treatment for Atrial...
November 16, 2017 08:30 ET | Source: ARCA biopharma, Inc.

ARCA Biopharma Announces Issuance of European Patent for Treating Cardiovascular Diseases and Conditions With a New Chemical Entity Utilizing Genetic Targeting

WESTMINSTER, Colo., Nov. 16, 2017 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right